DOI QR코드

DOI QR Code

A Systemic Analysis on Pemetrexed in Treating Patients with Breast Cancer

  • Wan, Fang (Department of Breast Surgery, Women's Hospital, School of Medicine, Zhejiang University) ;
  • Chen, Xin (Department of Breast Surgery, Women's Hospital, School of Medicine, Zhejiang University) ;
  • Dong, Li-Fan (Department of Breast Surgery, Women's Hospital, School of Medicine, Zhejiang University) ;
  • Cheng, Yue-Hong (Department of Breast Surgery, Women's Hospital, School of Medicine, Zhejiang University) ;
  • Long, Jing-Pei (Department of Breast Surgery, Women's Hospital, School of Medicine, Zhejiang University)
  • Published : 2014.06.15

Abstract

Background: This systemic analysis was conducted to evaluate the efficacy and safety of pemetrexed based chemotherapy in treating patients with metastatic breast cancer as first or second line chemotherapy. Methods: Clinical studies evaluating the efficacy and safety of pemetrexed based regimens on response and safety for patients with breast cancer were identified using a predefined search strategy. Pooled response rate (RR) of treatment were calculated. Results: In first line pemetrexed based regimens, 10 clinical studies which including 513 patients with advanced breast cancer were considered eligible for inclusion. For second line pemetrexed based chemotherapy, 5 clinical studies which including 281 patients with advanced breast cancer were considered eligible. Systemic analysis suggested that, in all patients, pooled RR was 32.6% (167/513) in pemetrexed based first line regimens, and 13.9 % (39/281) in pemetrexed based second line regimens. Major adverse effects were neutropenia, leukopenia, fatigue, and anemia in pemetrexed based first line treatment; and lymphopenia, neutropenia, leukopenia, as well as anemia in second line chemotherapy. One treatment related death occurred with pemetrexed based second line treatment. Conclusion: This systemic analysis suggests that pemetrexed based first line regimens are associated with a reasonable response rate and acceptable toxicity, however with low response rate for treating patients with metastatic breast cancer when is used in the second line.

References

  1. Akram M, Siddiqui SA (2012). Breast cancer management: Past, present and evolving. Breast Mini Symposium, 49, 277-282.
  2. Bonadonna G, Brusamolino E, Valagussa P, et al (1976). Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med, 294, 405-10. https://doi.org/10.1056/NEJM197602192940801
  3. Engin H, Bilir C, Tekin IO (2013). Prognostic significance of peripheral blood flow cytometry parameters in patients with non-metastatic breast cancer. Asian Pac J Cancer Prev, 14, 7645-9. https://doi.org/10.7314/APJCP.2013.14.12.7645
  4. Cabuk D, Basaran G, Teomete M, et al (2014). Clinical outcome of Turkish metastatic breast cancer patients with currently available treatment modalities--single center experience. Asian Pac J Cancer Prev, 15, 117-22. https://doi.org/10.7314/APJCP.2014.15.1.117
  5. Chin SN, Green CM, Gordon-Strachan GM, et al (2014). Locally advanced breast cancer in Jamaica: prevalence, disease characteristics and response to preoperative therapy. Asian Pac J Cancer Prev, 15, 3323-6. https://doi.org/10.7314/APJCP.2014.15.7.3323
  6. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 365, 1687-717. https://doi.org/10.1016/S0140-6736(05)66544-0
  7. Ferlay J, Bray F, Pisani P, et al (2004). Globocan 2002: Cancer Incidence, mortality and prevalence worldwide, Version 2.0. IARC Cancer Base No. 5. Lyon, France: IARC Press.
  8. Fouladi N, Ali-Mohammadi H, Pourfarzi F, et al (2014)Exploratory study of factors affecting continuity of cancer care: Iranian Women's perceptions. Asian Pac J Cancer Prev, 15, 133-7. https://doi.org/10.7314/APJCP.2014.15.1.133
  9. Garin A, Manikhas A, Biakhov M, et al (2008). A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat, 110, 309-15. https://doi.org/10.1007/s10549-007-9722-5
  10. Huang XE, Hirose K, Wakai K, et al (2004). Comparison of lifestyle risk factors by family history for gastric, breast, lung and colorectal cancer. Asian Pac J Cancer Prev, 5, 419-27.
  11. Majeed W, Aslam B, Javed I, et al (2014). Breast cancer: major risk factors and recent developments in treatment. Asian Pac J Cancer Prev, 15, 3353-8. https://doi.org/10.7314/APJCP.2014.15.8.3353
  12. Liu XH, Man YN, Wu XZ (2014). Recurrence season impacts the survival of epithelial ovarian cancer patients. Asian Pac J Cancer Prev, 15, 1627-32. https://doi.org/10.7314/APJCP.2014.15.4.1627
  13. Martin M (2006). Clinical experience with pemetrexed in breast cancer. Semin Oncol, 33, S15-8.
  14. Fouz N, Amid A, Hashim YZ (2013). Cytokinetic study of MCF-7 cells treated with commercial and recombinant bromelain. Asian Pac J Cancer Prev, 14, 6709-14. https://doi.org/10.7314/APJCP.2013.14.11.6709
  15. Gogia A, Raina V, Deo SV, et al (2014). Taxane and anthracycline based neoadjuvant chemotherapy for locally advanced breast cancer: institutional experience. Asian Pac J Cancer Prev, 15, 1989-92. https://doi.org/10.7314/APJCP.2014.15.5.1989
  16. Louisa M, Soediro TM, Suyatna FD (2014). In vitro modulation of P-glycoprotein, MRP-1 and BCRP expression by mangiferin in doxorubicin-treated MCF-7 cells. Asian Pac J Cancer Prev, 15, 1639-42. https://doi.org/10.7314/APJCP.2014.15.4.1639
  17. Moazzezy N, Farahany TZ, Oloomi M, et al (2014). Relationship between preoperative serum CA 15-3 and CEA levels and clinicopathological parameters in breast cancer. Asian Pac J Cancer Prev, 15, 1685-8. https://doi.org/10.7314/APJCP.2014.15.4.1685
  18. Niu HY, Niu CY, Wang JH, et al (2014). Health-related quality of life in women with breast cancer: a literature-based review of psychometric properties of breast cancer-specific measures. Asian Pac J Cancer Prev, 15, 3533-6. https://doi.org/10.7314/APJCP.2014.15.8.3533
  19. Rizalar S, Ozbas A, Akyolcu N, et al (2014). Effect of perceived social support on psychosocial adjustment of Turkish patients with breast cancer. Asian Pac J Cancer Prev, 15, 3429-34. https://doi.org/10.7314/APJCP.2014.15.8.3429
  20. Robert NJ, Conkling PR, O'Rourke MA, et al (2011). Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer. Breast Cancer Res Treat, 126, 101-8. https://doi.org/10.1007/s10549-010-1286-0
  21. Inanc M, Duran AO, Karaca H, et al (2014). Haematologic parameters in metastatic colorectal cancer patients treated with capecitabine combination therapy. Asian Pac J Cancer Prev, 15, 253-6. https://doi.org/10.7314/APJCP.2014.15.1.253
  22. Sipetic-Grujicic SB, Murtezani ZH, Neskovic-Konstatinovic ZB, et al (2014). Multivariate analysis of prognostic factors in male breast cancer in Serbia. Asian Pac J Cancer Prev, 15, 3233-8. https://doi.org/10.7314/APJCP.2014.15.7.3233
  23. Prajoko YW, Aryandono T (2014). Expression of nuclear factor kappa B (NF-${\kappa}B$) as a predictor of poor pathologic response to chemotherapy in patients with locally advanced breast cancer. Asian Pac J Cancer Prev, 15, 595-8. https://doi.org/10.7314/APJCP.2014.15.2.595
  24. Varol U, Yildiz I, Alacacioglu A, et al (2014). Anticancer therapy for breast cancer patients with skin metastases refractory to conventional treatments. Asian Pac J Cancer Prev, 15, 1885-7. https://doi.org/10.7314/APJCP.2014.15.4.1885
  25. Sedighi A, Hamed EA, Mohammadian K, et al (2013). Clinicopathologic characteristics of male breast cancer: a report of 21 cases in radiotherapy center of Hamedan, Iran. Asian Pac J Cancer Prev, 14, 7381-3. https://doi.org/10.7314/APJCP.2013.14.12.7381
  26. Wu LZ, Han RQ, Zhou JY, et al (2008). Incidence and mortality of female breast cancer in Jiangsu, China. Asian Pac J Cancer Prev, 15, 2727-32. https://doi.org/10.7314/APJCP.2014.15.6.2727
  27. Yadav D, Anwar MF, Garg V, et al (2014). Development of polymeric nanopaclitaxel and comparison with free paclitaxel for effects on cell proliferation of MCF-7 and B16F0 carcinoma cells. Asian Pac J Cancer Prev, 15, 2335-40. https://doi.org/10.7314/APJCP.2014.15.5.2335
  28. Yang L, Parkin DM, Ferlay J, et al (2005) . Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev, 14, 243-50.
  29. Yu KD, Di GH, Wu J, et al (2007). Development and trends of surgical modalities for breast cancer in China: A review of 16-year data. Ann Surg Oncol, 14, 2502-9. https://doi.org/10.1245/s10434-007-9436-2
  30. Zhu ZL, Zhang J, Chen ML, et al (2013). Efficacy and safety of trastuzumab added to standard treatments for HER2-positive metastatic breast cancer patients. Asian Pac J Cancer Prev, 14, 7111-6. https://doi.org/10.7314/APJCP.2013.14.12.7111